Companies · Pharmaceuticals

AudiaCare Inc.

GLEN GARDNER · Pharmaceuticals

Diligence memoA one-page analyst read on AudiaCare Inc. — recommendation, valuation, rhythm, risks.
$359K
Total raised · real
1
Rounds
8.3×
Latest step-up
Top 92%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Tue Mar 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

AudiaCare Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.90× the median modeled value of Pre-Seed Pharmaceuticals companies in 2016–2018 (56 peers) — value vs value, same stage and era.
  • Within the normal band (90% of peer median) for its niche.
Dormant
  • Last raise 10.3 yr ago; this sector typically re-raises about every 13 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

AudiaCare Inc. is one of 1610 Pharmaceuticals companies tracked from GLEN GARDNER. By capital raised it ranks in the long tail (ahead of 9% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
2015
Year incorporated
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2016-03-29 Raised $359K (real) Modeled valuation $17M (est)$359K$17MPre-Seed2016Seed · 2016-07-01 Raised $3.0M (real) Modeled valuation $114M (est)$3.0M$114MSeed2016+$3.0MCumulative $3.4M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$359K · 2016
Seed$3.0M · 2016

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$17.0M
Base estimate est.
$201K
Conservative case
$192.8M
Upside case
$2.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $17.0M · 2016-03-292016Seed · modeled $114.1M · 2016-07-012016
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
6.0 yr
Elapsed time used
10.3 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
3 mo
Avg between rounds
$1.4M/yr
Capital velocity
10.3 yr
On record since
2016
First round
2
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.0× of median
This company$359K
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 7.1× above median
This company$3.0M
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.2× of median
This company$17.0M
Sector median$76.1M

Raised more than 9% of sector peers (real $). Modeled value above 25% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #32 of 56.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Novellus LLC · Pre-Seed Raised $3.0M · modeled $47.3M (est)Blake Insomnia Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $47.3M (est)Essentia Pharma Socal, Llc · Pre-Seed Raised $1.0M · modeled $47.3M (est)Essentia Pharma Florida, Llc · Pre-Seed Raised $1.0M · modeled $47.3M (est)Eleusis Benefit Corporation, PBC · Pre-Seed Raised $1.7M · modeled $46.2M (est)Blc Usa Lp · Pre-Seed Raised $813K · modeled $38.5M (est)T.A.Z. Corp · Pre-Seed Raised $813K · modeled $38.5M (est)ReveraGen BioPharma, Inc. · Pre-Seed Raised $800K · modeled $37.8M (est)Cyto-Sen Therapeutics, Inc. · Pre-Seed Raised $800K · modeled $37.8M (est)WinSanTor · Pre-Seed Raised $783K · modeled $37.0M (est)Pelagius Inc. · Pre-Seed Raised $750K · modeled $35.5M (est)Apothecary Health Solutions, LLC · Pre-Seed Raised $725K · modeled $34.3M (est)AudiaCare Inc. (this company) Raised $359K · modeled $17.0M (est)AudiaCare Inc.
CompanyStageRaised · realValue · estvs peer med.
Novellus LLCPre-Seed$3.0M$47.3M2.50×
Blake Insomnia Therapeutics, Inc.Pre-Seed$1.0M$47.3M2.50×
Essentia Pharma Socal, LlcPre-Seed$1.0M$47.3M2.50×
Essentia Pharma Florida, LlcPre-Seed$1.0M$47.3M2.50×
Eleusis Benefit Corporation, PBCPre-Seed$1.7M$46.2M2.44×
Blc Usa LpPre-Seed$813K$38.5M2.03×
T.A.Z. CorpPre-Seed$813K$38.5M2.03×
ReveraGen BioPharma, Inc.Pre-Seed$800K$37.8M2.00×
Cyto-Sen Therapeutics, Inc.Pre-Seed$800K$37.8M2.00×
WinSanTorPre-Seed$783K$37.0M1.96×
Pelagius Inc.Pre-Seed$750K$35.5M1.87×
Apothecary Health Solutions, LLCPre-Seed$725K$34.3M1.81×
AudiaCare Inc. this companyPre-Seed$359K$17.0M0.90×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$359K2016-03-29$2.0M$17.0M90%
Seed$3.0M2016-07-01$15.0M$114.1M85%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$359K2016-03-29
    • First recorded raise — entered as Pre-Seed.
    • 13 investors on this round.
  2. Seed$3.0M2016-07-01
    • Came back fast: 3 mo vs the ~13 mo sector norm.
    • Round 8.3× larger than the prior — scaling up.
Intelligence
2016 ~Q4
Modeled next raise · ~3mo cadence
$9.0M
Modeled next size est.range $5.9M$14.4M
8.3×
Last step-up
$1.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Frances C Engoron2016-07
Isaac Treitel2016-03
James Tuan2016-03
Jennifer Seibert2016-03
Joseph A Walker2016-07
Kathleen Campbell2016-07
Stephanie C Pincus2016-03
Registry & provenance

AudiaCare Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1670536
SEC CIK
2015
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Avanti Pharma CorpPharmaceuticalsPre-Seed$350K$16.6Msame sector · same stage
Compassionate Buds, LLCPharmaceuticalsPre-Seed$350K$16.6Msame sector · same stage
Oncolinx Pharmaceuticals, LLCPharmaceuticalsPre-Seed$350K$16.6Msame sector · same stage
Tetra Bio-Pharma Inc.PharmaceuticalsPre-Seed$371K$17.5Msame sector · same stage
LIPAC Oncology LLCPharmaceuticalsPre-Seed$373K$17.6Msame sector · same stage
J2 Bio-Pharma, LLCPharmaceuticalsPre-Seed$345K$16.3Msame sector · same stage
ApoVax, Inc.PharmaceuticalsPre-Seed$375K$5.9Msame sector · same stage
Joint Venture Pharmacy TX-01, LLCPharmaceuticalsPre-Seed$375K$17.7Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
CASI Pharmaceuticals, Inc.PharmaceuticalsSeries A$12.3M82%
Acura Pharmaceuticals, IncPharmaceuticalsSeed$152.2M82%
Marius Pharmaceuticals, LLCPharmaceuticalsSeries B$129.3M82%
Vireo Health, Inc.PharmaceuticalsSeries B$547.2M81%
Acta Pharmaceuticals, Inc.PharmaceuticalsSeries A$121.3M80%
ResBiotic, Inc.PharmaceuticalsSeed$42.9M80%
Amplicore Inc.PharmaceuticalsSeed$107.1M80%
SiO2 Medical Products, Inc.PharmaceuticalsSeries C$1.7B80%
Frequently asked
How much funding has AudiaCare Inc. raised?
AudiaCare Inc. has raised approximately $359K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is AudiaCare Inc.'s estimated valuation?
Provath's modeled valuation for AudiaCare Inc. is approximately $17.0M (modeled range $201K–$192.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is AudiaCare Inc. at?
AudiaCare Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Tue Mar 29.
What does AudiaCare Inc. do and where is it based?
AudiaCare Inc. operates in the Pharmaceuticals sector, based in GLEN GARDNER.
Explore related

See where AudiaCare Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at AudiaCare Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.